A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
Abstrak
The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China. Seventy-three (52.1%) patients diagnosed as MDS with ring sideroblasts (MDS-RS) following the 2016 World Health Organization (WHO) classification and 118 (84.3%) patients belonged to lower risk following the revised International Prognostic Scoring System (IPSS-R). Although clonal hematopoiesis-associated mutations containing TET2, ASXL1 and DNMT3A were the most frequent co-mutant genes in these patients, RUNX1, EZH2, NF1 and KRAS/NRAS mutations had significant effects on overall survival (OS). Based on that we developed a risk scoring model as IPSS-R×0.4+RUNX1×1.1+EZH2×0.6+RAS×0.9+NF1×1.6. Patients were categorized into two subgroups: low-risk (L-R, score <= 1.4) group and high risk (H-R, score > 1.4) group. The 3-year OS for the L-R and H-R groups was 91.88% (95% CI, 83.27%-100%) and 38.14% (95% CI, 24.08%-60.40%), respectively (P<0.001). This proposed model distinctly outperformed the widely used IPSS-R. In summary, we constructed and validated a personalized prediction model of MDS patients with SF3B1 mutation that can better predict the survival of these patients.
Topik & Kata Kunci
Penulis (29)
Liya Ma
Bin Liang
Huixian Hu
Wenli Yang
Shengyun Lin
Lihong Cao
Kongfei Li
Yuemin Kuang
Lihong Shou
Weimei Jin
Jianping Lan
Xingnong Ye
Xingnong Ye
Jing Le
Huyi Lei
Jiaping Fu
Ying Lin
Wenhua Jiang
Zhiying Zheng
Songfu Jiang
Lijuan Fu
Chuanyong Su
XiuFeng Yin
Lixia Liu
Jiayue Qin
Jie Jin
Shenxian Qian
Guifang Ouyang
Hongyan Tong
Akses Cepat
- Tahun Terbit
- 2022
- Sumber Database
- DOAJ
- DOI
- 10.3389/fonc.2022.905490
- Akses
- Open Access ✓